CYTK
Cytokinetics Incorporated
$63.59
+$1.34(+2.15%)
59
Overall
40
Value
91
Tech
47
Quality
Market Cap
$5.82B
Volume
2.43M
52W Range
$29.31 - $64.13
Target Price
$76.26
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $28.7M | $106.4M | $13.4M | $31.5M | $26.9M | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | ||
| Total Revenue | $28.7M | $106.4M | $13.4M | $31.5M | $26.9M | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $28.7M | $106.4M | $13.4M | $31.5M | $26.9M | $-41.1M | $-89.5M | $-146.2M | $7.5M | $-320.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-66.1M | $-87.7M | $-126.8M | $-120.4M | $125.7M | $149.8M | $256.7M | $178.0M | $503.7M | $554.7M | ||
| Research & Development | $46.4M | $59.9M | $90.3M | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | ||
| Research Expense | $46.4M | $59.9M | $90.3M | $89.1M | $86.1M | $97.0M | $159.9M | $240.8M | $330.1M | $339.4M | ||
| Selling, General & Administrative | $19.7M | $27.8M | $36.5M | $31.3M | $39.6M | $52.8M | $96.8M | $178.0M | $173.6M | $215.3M | ||
| General & Administrative Expenses | $19.7M | $27.8M | $36.5M | $31.3M | $39.6M | $52.8M | $96.8M | $178.0M | $173.6M | $215.3M | ||
| Salaries & Wages | $-4.6M | $-7.1M | $-9.0M | $-9.8M | -- | -- | -- | -- | $72.1M | $97.8M | ||
| Depreciation & Amortization | $-600.0K | $-700.0K | $-1.9M | $-1.2M | $1.3M | $1.8M | $2.3M | $5.8M | $11.9M | $9.5M | ||
| Depreciation & Amortization | $-600.0K | $-700.0K | $-1.9M | $-1.2M | $1.3M | $1.8M | $2.3M | $5.8M | $11.9M | $9.5M | ||
| Amortization | -- | -- | -- | -- | $66.0K | $79.0K | $112.0K | -- | -- | -- | ||
| Other Operating Expenses | $-441.0K | $-845.0K | $-1.8M | $-110.0K | $-447.0K | $-603.0K | $-802.0K | $-4.4M | $-7.0M | $-5.9M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-37.4M | $18.7M | $-113.4M | $-88.9M | $-98.9M | $-93.9M | $-186.3M | $-324.2M | $-496.2M | $-536.2M | ||
| EBITDA | $-36.7M | $18.0M | $-108.9M | $-85.2M | $-95.6M | $-86.8M | $-183.7M | $-332.0M | $-501.8M | $-574.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $268.0K | $2.7M | $3.0M | $3.8M | $6.6M | $38.7M | $29.3M | $51.2M | $28.3M | $37.7M | ||
| Intinc | $174.0K | $464.0K | $2.6M | $4.2M | $4.5M | $5.3M | $1.0M | $11.4M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-94.0K | $-2.2M | $-414.0K | $394.0K | $-6.6M | $-16.0M | $-16.4M | $39.8M | $-28.3M | $-37.7M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.3M | ||
| Other Income/Expense | -- | -- | -- | $-100.0K | $-4.5M | $-5.3M | $-331.0K | $-24.9M | $-27.6M | $-52.8M | ||
| Other Special Charges | -- | -- | -- | -- | $4.5M | $5.3M | $331.0K | $11.3M | $27.6M | $51.5M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | $4.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $2.8M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-37.3M | $17.3M | $-110.8M | $-84.7M | $-94.3M | $-88.6M | $-186.0M | $-337.8M | $-497.9M | $-551.8M | ||
| Pre-Tax Income | $-37.5M | $16.5M | $-113.8M | $-88.5M | $-101.0M | $-104.6M | $-202.4M | $-389.0M | $-496.9M | $-589.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-1.0K | $-1.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-37.5M | $16.5M | $-127.8M | $-106.3M | $-121.7M | $-127.3M | $-215.3M | $-389.0M | $-526.2M | $-589.5M | ||
| Net Income (Continuing Operations) | $-37.5M | $16.5M | $-127.8M | $-106.3M | $-121.7M | $-127.3M | $-215.3M | $-389.0M | $-526.2M | $-589.5M | ||
| Net Income (Discontinued Operations) | $-37.5M | $16.5M | $-127.8M | $-106.3M | $-121.7M | $-127.3M | $-215.3M | $-389.0M | $-526.2M | $-589.5M | ||
| Net Income (Common Stockholders) | $-37.5M | $16.5M | $-127.8M | $-106.3M | $-121.7M | $-127.3M | $-215.3M | $-389.0M | $-526.2M | $-589.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-515.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-66.1M | $-87.7M | $-126.8M | $-120.4M | $125.7M | $149.8M | $256.7M | $418.8M | $503.7M | $554.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $38.8M | $39.9M | $49.4M | $54.4M | $57.6M | $64.5K | $76.9K | $89.8K | $96.5K | $112.0K | ||
| Average Shares Outstanding (Diluted) | $38.8M | $42.6M | $49.3M | $54.5M | $57.6M | $64.5K | $76.9K | $89.8K | $96.5K | $112.0K | ||
| Shares Outstanding | $39.6M | $41.7M | $54.0M | $54.9M | $59.5M | $71.1M | $84.9M | $95.2M | $103.0M | $118.4M | ||
| Basic EPS | $-0.97 | $0.41 | $-2.59 | -- | $-2.11 | $-1.97 | $-2.8 | $-4.33 | $-5.45 | $-5.26 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-2.11 | $-1.97 | $-2.8 | $-4.33 | $-5.45 | $-5.26 | ||
| Diluted EPS | $-0.97 | $0.39 | $-2.59 | $-1.95 | $-2.11 | $-1.97 | $-2.8 | $-4.33 | $-5.45 | $-5.26 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-4.33 | $-5.45 | $-5.26 | ||
| OTHER METRICS | ||||||||||||
| Interest Expense Operating | $-94.0K | $-1.9M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | -- | $-14.0M | $-17.8M | $-20.7M | $-22.7M | $-12.9M | $-56.7M | -- | -- | ||
| Non Recurring Operation Expense | -- | $-4.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $19.7M | $27.8M | $36.5M | $31.3M | $39.6M | $52.8M | $96.8M | $178.0M | $173.6M | $215.3M | ||
| Rent And Landing Fees | $19.7M | $27.8M | $36.5M | $31.3M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CYTK | $63.59 | +2.2% | 2.43M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cytokinetics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW